SINOMAB BIO-B (03681.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Sep4

China Antibody-B Reaches New High, Continues to Optimize Operational Quality

02:06

Aug30

China Antibody reports reduced loss of RMB 49.821 million for the first half of 2025

09:41

Aug29

SINOMAB BIO-B released FY2025 Q1 earnings on August 29 (BJT), actual revenue HKD 5.238 M, actual EPS HKD -0.0243

15:00

China Biology-B Reports Strong Mid-Year Earnings and Advances in Core Drug Pipeline

13:22

China Antibody-B Completes Placement of 24,965,400 Shares

11:02

SINOMAB BIO-B released FY2025 Semi-Annual Earnings on August 29 During-Market BJT, actual revenue HKD 10.59 M, actual EPS HKD -0.0492

08:00

Schedules & Filings

Schedules

Filings

Aug29

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 5.353 M, Net Income -27.27 M, EPS -0.0248

Mar31

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue -2.157 M, Net Income -50.28 M, EPS -0.0467

Aug19

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 3.267 M, Net Income -48.69 M, EPS -0.0454

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change